Johnson & Johnson to buy Momenta for about $6.5 billion


Johnson & Johnson mentioned on Wednesday it might purchase Momenta Prescription drugs for about $6.5 billion in money to bolster its portfolio of remedies for autoimmune ailments.

Momenta shares had been up 68% at $51.98 earlier than the bell, simply shy of the provide worth of $52.20.

The deal offers Johnson & Johnson’s Janssen unit entry to Momenta’s experimental remedy, nipocalimab, being examined for myasthenia gravis, a neuromuscular illness that causes weak spot in muscular tissues.

“Nipocalimab offers Janssen the chance to succeed in considerably extra sufferers by pursuing indications throughout many autoimmune ailments,” Johnson & Johnson mentioned in a press release.

The drug is being developed to deal with ailments the place the physique’s personal antibodies assault or injury proteins and cells.

J&J reiterated its 2020 adjusted earnings per share forecast and mentioned it anticipated the deal to shut within the second half of 2020.


Please enter your comment!
Please enter your name here